title: When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia.
abstract: Currently available antipsychotic drugs target dopaminergic neurotransmission. Many patients do not respond fully to these treatments, and there has been considerable effort to investigate alternative targets. Here we summarise the rationale and recent evidence supporting efforts to develop glutamatergic antipsychotic drugs.
authors: Institute of Psychiatry, King's College London, Department of Psychosis Studies, De Crespigny Park, Denmark Hill, London, UK. evangelos.papanastasiou@kcl.ac.uk
authors: Evangelos
authors: E
authors: Papanastasiou
authors: James M
authors: JM
authors: Stone
authors: Sukhi
authors: S
authors: Shergill
mesh_terms: D000494:Allosteric Regulation; D014150:Antipsychotic Agents / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D018683:Excitatory Amino Acid Agents / Q000494:pharmacology*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D017470:Receptors, Glutamate / Q000187:drug effects*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D017211:Treatment Failure
chemical_list: D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D018683:Excitatory Amino Acid Agents; D017470:Receptors, Glutamate